Networks of Centres of Excellence of Canada
Government of Canada

Common menu bar links

Centre for Commercialization of Cancer Immunotherapy - C3i

$15 million for 2016-21
About   |   News
Centre for Commercialization of Cancer Immunotherapy

Number of partners

Partner contributions
$3 million

Montréal, Quebec

Francois Bettez Francois Bettez

Chief Medical Officer
Lambert Busque Lambert Busque

Board chair
Louis Lacasse Louis Lacasse

Accelerating the immunotherapy cancer care revolution

The opportunity

Immunotherapy is a rapidly emerging practice that harnesses the power of the immune system to combat cancer. It could revolutionize cancer care by developing nontoxic, highly efficient and decisive cures that do not rely on chemotherapeutic agents, thus improving patients’ quality of life and reducing healthcare costs. These treatments could be used in 60% of advanced cancer patients by 2025. Canada needs greater capacity to translate these therapies into patient care, and to help Canadian companies compete in a potential $40 billion market.

How C3I is seizing the opportunity

The Centre for Commercialization of Cancer Immunotherapy (C3i) will accelerate access to innovative cancer immunotherapies for patients. Operating out of the Hôpital Maisonneuve-Rosemont installation of the Integrated University Center of East Montreal (CIUSS de l’Est-de-l’île-de-Montréal), the centre will offer an integrated structure for the development, translation and commercialization of these groundbreaking therapies. C3i will combine three interacting units that will provide patients with cutting edge biomarker and diagnostics tests, good manufacturing practices standards and rapid access to clinical trials and regulatory support to bring effective and affordable remedies more rapidly to Canadians and the world. This will strengthen Canada’s position as a leader in the emerging field of cancer immunotherapy.

Among the results

  • C3i in partnership with the Center of Excellence in Cellular therapy, a GMP facility located at Hôpital Maisonneuve Rosemont in Montreal has secured several manufacturing agreements in cancer immunotherapy with academic and private sector partners. These agreements will pave the way for Canadian health professionals and patients to gain early access to promising therapies at the developmental stage.
  • C3i has supported financially two Canadian biotech startups in their drug development program. This is in line with our objective to bring new treatment options for cancer patients while supporting Canadian research breakthroughs.
  • C3i has interconnected a Biomarker and Diagnostic Unit, a GMP facility, a Clinical Research Unit, a large patient base , with entrepreneurial expertise providing a One Stop Shop for the development of Cancer Immunotherapy

Connect with C3i